Examples of head impulse test (HIT) results. (1) Posterior circulation stroke (PCS) and vestibular neuritis (VN). Examples of HIT in PCS and VN, displayed as time series of inverted eye (ipsilesional: green, contralesional: blue) to head (red) impulse velocities. (A) In VN, ipsilateral gain deficit (mean 0.16) led to large overt (black arrows) saccades (cumulative amplitude: 9.1°, mean) and frequent covert saccades (73% of trials). Contralesional gain was mildly reduced (0.72), matched by small overt saccades (1.2°). Saccades occurring in the direction of contralesional impulses (#) were quick phases of spontaneous nystagmus. (B) In anterior inferior cerebellar artery-peripheral (AICAp) stroke due to left vestibular nuclear infarction (white arrow), gains were bilaterally deficient (ipsilesional: 0.11, contralesional: 0.21) and overt saccades were present bilaterally, larger after ipsilesional (5.7°) than contralesional (3.3°) trials. Compared to VN, overt saccades were 63% smaller after ipsilesional trials but 2.8 times larger after contralesional trials. Anticompensatory saccades (∧) were dominant after contralesional trials. (C) In anterior inferior cerebellar artery-central (AICAc) stroke due to isolated right floccular infarction, gains were asymmetrically reduced (ipsilesional: 0.55, contralesional: 0.75) with few small overt saccades (ipsilesional trials: 2.7°, contralesional trials: 2.1°). (D) Upper: in posterior inferior cerebellar artery (PICA) stroke involving the left cerebellar hemisphere and nodulus (white arrowhead), gains were symmetrical (ipsilesional: 0.85, contralesional: 0.82) with frequent overt saccades, larger after contralesional (4.3°) than ipsilesional (2.8°) trials. Lower: in superior cerebellar artery (SCA) stroke involving the superior vermis, gains were mildly reduced bilaterally (ipsilesional: 0.66, contralesional: 0.71) with small overt saccades (ipsilesional trials: 2.2°, contralesional trials: 1.2°). Reproduced from the study by Chen et al. (104), used with permission from Wolters Kluwer Health, Inc.